Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

[pre]Actual Study Start Date : July 1, 2020

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Investor2014 Member Profile
 
Followed By 28
Posts 13,429
Boards Moderated 0
Alias Born 11/23/16
160x600 placeholder
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (b... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire Inc. - 11/25/2020 7:00:00 AM
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Demen... GlobeNewswire Inc. - 11/6/2020 10:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 7:05:29 AM
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-... GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire Inc. - 9/10/2020 7:00:10 AM
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for C... GlobeNewswire Inc. - 8/19/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 4:11:04 PM
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Pa... GlobeNewswire Inc. - 8/5/2020 4:05:10 PM
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 GlobeNewswire Inc. - 8/4/2020 7:00:10 AM
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 7/6/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 6:26:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/2/2020 6:25:15 PM
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in P... GlobeNewswire Inc. - 7/1/2020 7:00:10 AM
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome ... GlobeNewswire Inc. - 6/16/2020 7:00:10 AM
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcames... GlobeNewswire Inc. - 6/4/2020 7:00:10 AM
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 5/21/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:41:44 PM
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 5/7/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020 GlobeNewswire Inc. - 5/5/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2020 7:08:41 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:08:14 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:03:26 AM
Investor2014   Friday, 10/23/20 02:09:44 PM
Re: abew4me post# 278163
Post # of 286197 

Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : July 2021



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences